Randomized, double-blind trial of Lithostat (acetohydroxamic acid) in the palliative treatment of infection-induced urinary calculi.
In a prospective, double-blind, placebo-controlled study, the efficacy and safety of acetohydroxamic acid (AHA) in preventing urinary calculogenesis was evaluated in 94 patients with chronic urinary infection. Stone growth occurred in 17% of the AHA group and in 46% of the placebo group (p less than 0.005). Completely reversible side effects consisting predominantly of psychoneurologic and musculo-integumentary symptoms were more prevalent in the AHA group (p less than 0.01). Side effects which were judged 'intolerable' were experienced by 10 (22.2%) of patients in the AHA group and 2 (4.1%) in the placebo group. It is concluded that AHA treatment is effective, relatively safe, and clinically useful in preventing infection-induced urinary calculogenesis.
Griffith
D P
DP
Scott Department of Urology, Baylor College of Medicine, Houston, Tex.
Gleeson
M J
MJ
Lee
H
H
Longuet
R
R
Deman
E
E
Earle
N
N
D000328:Adult; D000368:Aged; D001437:Bacteriuria / Q000150:complications*; D002908:Chronic Disease; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use; D008274:Magnesium; D017616:Magnesium Compounds; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D010710:Phosphates; D010919:Placebos; D011446:Prospective Studies; D000069877:Struvite; D014545:Urinary Calculi / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control
D006877:Hydroxamic Acids; D017616:Magnesium Compounds; D010710:Phosphates; D010919:Placebos; C006358:acetohydroxamic acid; D000069877:Struvite; D008274:Magnesium